Suchergebnisse - "Salari, Sina"

PubPharm (69)

1

Lung cancer vaccination from concept to reality : A critical review of clinical trials and latest advances

enthalten in: Life sciences | 2024

von Sanaei, M. | Pourbagheri-Sigaroodi, A. | Rezvani, A. | +4

2

Breast cancer vaccination : Latest advances with an analytical focus on clinical trials

enthalten in: International immunopharmacology | 2023

von Vajari, M. | Sanaei, M. | Salari, S. | +3

3

Maintenance therapy with Everolimus in patients with refractory or relapsing Hodgkin lymphoma after autologous stem cell transplantation

enthalten in: Blood cell therapy | 2023

von Mehdizadeh, M. | Tehrani, H. | Rezvani, H. | +3

4

Investigation of Expression Profile of Placenta-specific 1 (PLAC1) in Acute Myeloid and Lymphoid Leukemias

enthalten in: Avicenna journal of medical biotechnology | 2023

von Gholami, P. | Asgarian-Omran, H. | Yaghmaie, M. | +7

5

Involvement Value of FLT-3, c-Myc, STAT3, p27, and HOTAIR Gene Expression in Acute Myeloid Leukemia Patients : A Molecular Perspective to a Novel Leukemogenesis Mechanism

enthalten in: International journal of hematology-oncology and stem cell research | 2023

von Shagerdi Esmaeli, N. | Asadi, S. | Bashash, D. | +2

6

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer

enthalten in: Journal of education and health promotion | 2023

von Kianersi, S. | Salari, S. | Rezvani, H. | +4

7

Proteome Analysis of Adult Acute Lymphoblastic Leukemia by Two-dimensional Blue Native/Sodium Dodecyl Sulfate Gel Electrophoresis

enthalten in: Avicenna journal of medical biotechnology | 2023

von Bagheralmoosavi, S. | Gholami, P. | Amini, M. | +8

8

Evaluation of the Effect of Carvedilol in Preventing Right Ventricular Dysfunction in Breast Cancer Patients Receiving Anthracycline

enthalten in: Advanced biomedical research | 2023

von Karvandi, M. | Ghadyani, M. | Mohebbi, N. | +2

9

Correction : Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

enthalten in: BMC cancer | 2022

von Allahyari, A. | Ehsanpour, A. | Najafi, B. | +30

ErratumFor: BMC Cancer. 2022 Sep 7;22(1):960. - PMID 36071409

10

Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial

enthalten in: BMC cancer | 2022

von Allahyari, A. | Ehsanpour, A. | Najafi, B. | +30

1
2
3
4
5
6
7
Nächster »
[7]